Focus: Sangamo Therapeutics is a biotechnology company specializing in gene therapy and cell therapy biologics across neurology, infectious diseases, rare diseases, metabolic diseases, and nephrology. The company operates as a mid-cap biotech with a diversified pipeline but no currently marketed products.
Profile data last refreshed 12h ago · AI intelligence enriched 1w ago
Recent layoff filing — 4 affected
Source: state DOL filings via Big Local News
Sangamo offers exposure to advanced therapeutic modalities with meaningful pipeline breadth, but lack of Phase 3 advancement and recent workforce reduction suggest elevated execution risk.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sangamo Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sangamo Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent workforce reduction despite active pipeline indicates operational stress; near-term stability cannot be assumed.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo